http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022128708-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61674c04205a0c2e6242604d823b53ff |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate | 2021-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5561bf6eb2db3f65e091df3e864e844b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca83d04b2e67acf7f991a9e511465cd3 |
| publicationDate | 2022-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022128708-A1 |
| titleOfInvention | Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients |
| abstract | The invention relates to methods based on gene expression levels to predict treatment response to an anti-TNFalpha compound in inflammatory bowel disease patients based on a pre-treatment biopsy, and a method of determining the treatment effectiveness of such treatment based on a biopsy obtained after initiation of the treatment with an anti-TNFalpha compound. The prediction is based on the determination of cellular signaling pathway activity, in particular a pathway selected from TGFbeta, NFkB, MAPK-AP1, STAT3 and WNT, preferably wherein the cellular signaling pathway is selected from TGFbeta and NFkB. When determining the treatment effectiveness, the cellular signaling pathway is AR and/or MAPK- AP1 if the IBD is UC and wherein if the IBD is CD, the cellular signaling pathway is MAPK-AP1 and/or NFkB. The invention further relates to the use of anti-TNFalpha compounds in the treatment of Inflammatory bowel disease wherein the treatment is combined with the method for predicting treatment response and only administered when a favorable response is predicted. Lastly, the invention relates to kits and uses thereof in the methods described herein. |
| priorityDate | 2020-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1088.